Hoth Therapeutics’ (HOTH) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Hoth Therapeutics (NASDAQ:HOTH) in a report issued on Thursday,Benzinga reports. The brokerage currently has a $4.00 target price on the stock.

Other equities analysts also recently issued research reports about the stock. Benchmark reaffirmed a “speculative buy” rating and issued a $3.00 price objective on shares of Hoth Therapeutics in a report on Friday, October 11th. D. Boral Capital reaffirmed a “buy” rating and set a $5.00 price objective on shares of Hoth Therapeutics in a research report on Tuesday, January 7th.

Hoth Therapeutics Stock Up 8.1 %

Shares of HOTH opened at $1.47 on Thursday. The firm has a market cap of $10.14 million, a price-to-earnings ratio of -1.11 and a beta of 0.75. The business’s 50 day moving average is $1.02 and its two-hundred day moving average is $0.91. Hoth Therapeutics has a 52-week low of $0.58 and a 52-week high of $3.80.

Hoth Therapeutics (NASDAQ:HOTH) last released its earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.01). On average, equities analysts expect that Hoth Therapeutics will post -1.18 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Hoth Therapeutics stock. Virtu Financial LLC purchased a new stake in shares of Hoth Therapeutics, Inc. (NASDAQ:HOTH) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 32,636 shares of the company’s stock, valued at approximately $29,000. Virtu Financial LLC owned 0.47% of Hoth Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). 7.08% of the stock is owned by institutional investors.

Hoth Therapeutics Company Profile

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.